Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Freneslerbart
REGN1908 · 1 trial · 1 indication
Assessed using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale, a 0-4 point scale where 0= none and 4= incapacitating itch, 0.5 unit increments
| Arm | Type | Description |
|---|---|---|
| REGN1908-1909 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| REGN1908 | DRUG | Administered per the protocol |
| REGN1909 | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Documented or participant-reported history of moderate to severe cat allergy for at least 2 years with bothersome ocular symptoms being near cat(s) 2. Positive SPT with cat allergen extract (mean wheal diameter at least 5 mm greater than the negative control) at screening...
REGN1908 is being developed for allergic conjunctivitis, specifically ocular allergy signs and symptoms in adults with cat allergy. It is a small molecule therapeutic candidate from Regeneron Pharmaceuticals. The clinical program has focused on reducing eye allergy symptoms triggered by cat allergen exposure in adult participants.
REGN1908 targets FelD1, the major cat allergen protein. By binding to FelD1, the drug is designed to interfere with the allergen that triggers allergic responses in sensitized individuals. This target class is an allergen, distinguishing it from antibody or receptor targets typical of other allergy therapies.
REGN1908 is being developed by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker REGN. Regeneron is the sponsor of the clinical program evaluating the drug in allergic conjunctivitis for patients with cat allergy.
REGN1908 is in Phase 3 clinical development. A Phase 3 trial has been completed, and the drug remains investigational. It has not been approved by the FDA for any indication. The completed Phase 3 study enrolled 64 participants and evaluated the drug in adults with cat allergy.
REGN1908 has been studied in one completed Phase 3 trial, NCT06602726, titled A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy. The trial enrolled 64 adults, was randomized, double-blind, and placebo-controlled, and took place in the United States and Canada.